Journal of Mid-life Health Journal of Mid-life Health
Home | About us | Editorial board | Search | Ahead of print | Current Issue | Past Issues | Instructions | Online submission | Subscribe | Advertise Users Online: 806  Print this pageEmail this pageSmall font sizeDefault font sizeIncrease font size 


CASE REPORT
Year : 2018  |  Volume : 9  |  Issue : 4  |  Page : 210-211

Malignant mixed mullerian tumor secondary to tamoxifen for Ca breast: Shadow of the past!


1 Department of Obstetrics and Gynaecology, S. P. Medical College, Bikaner, Rajasthan, India
2 Department of Obstetrics and Gynaecology, SMS Medical College, Jaipur, Rajasthan, India

Correspondence Address:
Vinu Choudhary
Department of Obstetrics and Gynaecology, SMS Medical College, Jaipur, Rajasthan
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/jmh.JMH_79_18

Rights and Permissions

Tamoxifen is used in the treatment of hormone-responsive breast cancer because of its antiestrogenic effect. However, it also has an estrogenic effect on the uterus, thereby increasing the risk of endometrial hyperplasia, endometrial polyp, and malignant mixed Mullerian tumor (MMMT). This case describes the pathogenesis and risk of MMMT due to long-term tamoxifen intake in hormone-responsive breast cancer.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed220    
    Printed2    
    Emailed0    
    PDF Downloaded26    
    Comments [Add]    

Recommend this journal